Table 3.
Baseline characteristics of study participants with serum 25-hydroxyvitamin D levels < 50 nmol/l at baseline
| All study participants (n = 39) | Vitamin D (n = 19) | Placebo (n = 20) | p value | ||||
|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | ||
| Age (years) | 47 | 32–53 | 46 | 35–52 | 49 | 32–54 | 0.858 |
| BMI (kg/m2) | 29.8 | 26.5–34.2 | 31.2 | 26.5–33.9 | 29.4 | 26.4–34.3 | 0.609 |
| 25-Hydroxyvitamin D (nmol/l) | 41 | 35–45 | 41 | 34–45 | 41 | 37–44 | 0.904 |
| PTH (pg/ml) | 49.4 | 42.2–60.8 | 49.3 | 35.7–65.5 | 51.1 | 42.4–59.0 | 0.743 |
| Serum calcium (mmol/l) | 2.36 | 2.31–2.39 | 2.37 | 2.34–2.44 | 2.34 | 2.30–2.39 | 0.060 |
| Urine calcium (mmol/l) | 3.06 | 1.96–4.32 | 2.57 | 1.19–3.88 | 3.19 | 2.69–4.44 | 0.272 |
| Total testosteronea (nmol/l) | 12.2 | 9.7–16.2 | 12.0 | 10.6–16.5 | 12.3 | 9.6–16.1 | 0.910 |
| Total testosterone immunoassay (nmol/l)b | 8.7 | 7.0–10.0 | 8.7 | 7.3–10.0 | 8.8 | 7.0–9.9 | 0.687 |
| Free testosterone (ng/ml) | 0.073 | 0.056–0.091 | 0.071 | 0.058–0.088 | 0.076 | 0.053–0.093 | 0.911 |
| SHBG (nmol/l) | 27.4 | 19.5–42.4 | 27.1 | 16.2–44.4 | 28.0 | 20.1–42.0 | 0.559 |
| Free androgen index | 39.1 | 29.0–65.1 | 39.1 | 29.3–63.6 | 37.9 | 28.8–66.0 | 0.789 |
| Estradiol (ng/ml) | 34.5 | 26.4–47.4 | 34.2 | 26.9–53.4 | 35.4 | 24.4–41.7 | 0.239 |
| FSH (mU/ml) | 4.8 | 3.1–6.8 | 5.0 | 3.3–6.8 | 3.5 | 2.7–7.7 | 0.351 |
| LH (mU/ml) | 3.4 | 2.6–4.6 | 3.4 | 2.6–4.6 | 3.3 | 2.3–5.6 | 0.633 |
| HOMA-IR | 3.1 | 2.1–5.4 | 3.1 | 1.9–5.9 | 3.2 | 2.2–5.3 | 0.948 |
| HOMA-β | 179.5 | 118.7–251.6 | 131.4 | 85.0–251.6 | 196.3 | 137.3–255.0 | 0.096 |
| MATSUDA-index | 3.9 | 1.9–5.6 | 3.6 | 2.1–5.3 | 4.1 | 1.9–5.6 | 0.689 |
| QUICKI | 0.32 | 0.30–0.34 | 0.32 | 0.30–0.35 | 0.32 | 0.30–0.34 | 0.415 |
| AUCglucose | 261.5 | 222.0–304.5 | 261.3 | 220.5–312.3 | 262.0 | 222.0–287.3 | 0.370 |
| AUCinsulin | 126.8 | 73.9–216.4 | 125.2 | 89.4–222.4 | 136.0 | 23.5–210.5 | 0.961 |
| Total cholesterol (mg/dl) | 215 | 179–233 | 202 | 166–233 | 216 | 196–235 | 0.420 |
| HDL-C (mg/dl) | 49 | 41–61 | 48 | 42–61 | 50 | 41–61 | 0.818 |
| LDL-C (mg/dl) | 130 | 101–145 | 129 | 101–144 | 131 | 106–161 | 0.716 |
| Triglycerides (mg/dl) | 131 | 82–179 | 129 | 99–174 | 139 | 63–181 | 0.381 |
| Fat mass (kg) | 31.6 | 25.3–39.9 | 31.6 | 25.9–39.9 | 31.3 | 23.9–39.9 | 0.797 |
| Lean mass (kg) | 58.0 | 55.2–65.4 | 61.7 | 51.4–65.6 | 58.0 | 56.4–62.6 | 0.897 |
| AMS score | 27 | 21–31 | 23 | 19–32 | 28 | 25–31 | 0.114 |
| IIEF-EF score | 28 | 23–30 | 28 | 24–30 | 26 | 23–30 | 0.671 |
Comparisons of baseline characteristics between men in the vitamin D and the placebo group were performed using student’s T test
HOMA-IR homeostatic model assessment-insulin resistance, QUICKI quantitative insulin sensitivity check index, AUC area under the curve, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, AMS Aging Male’s Symptoms Questionnaire, IIEF-EF International Index of Erectile Function—Erectile Function Questionnaire
aTotal testosterone measured by ID-LC–MS/MS
bTotal testosterone measured by immunoassay